KPL-387

DRUG3 trials

Sponsors

Kiniksa Pharmaceuticals GmbH, Kiniksa Pharmaceuticals International, plc

Conditions

Heart DiseasesPericarditisPericarditis AcuteRecurrent PericarditisWell-Controlled Recurrent Pericarditis

Phase 2

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

RecruitingNCT07010159

Kiniksa Pharmaceuticals International, plcPericarditis, Pericarditis Acute, Recurrent Pericarditis

Start: 2025-07-25End: 2029-12-31Target: 325Updated: 2026-08-26

Transition to KPL-387 Monotherapy Dosing & Administration Study

RecruitingNCT07288216

Kiniksa Pharmaceuticals International, plcHeart Diseases, Pericarditis, Recurrent Pericarditis

Start: 2026-03-25End: 2029-12-31Target: 80Updated: 2026-08-11

A Phase 2 Posology Study with Long-Term Extension in Participants with Well‑Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies

Not yet recruitingCTIS2025-523234-66-00

Kiniksa Pharmaceuticals GmbHWell-Controlled Recurrent Pericarditis

Target: 14Updated: 2026-03-20